Free Trial

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare logo
$383.21 +3.91 (+1.03%)
As of 03:58 PM Eastern

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
7
Buy
12

Based on 19 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 7 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for HCA.

Consensus Price Target

$395.71
3.26% Upside
According to the 19 analysts' twelve-month price targets for HCA Healthcare, the average price target is $395.71. The highest price target for HCA is $440.00, while the lowest price target for HCA is $336.00. The average price target represents a forecasted upside of 3.26% from the current price of $383.21.
Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

Sign Up

HCA Analyst Ratings Over Time

TypeCurrent Forecast
6/30/24 to 6/30/25
1 Month Ago
5/31/24 to 5/31/25
3 Months Ago
4/1/24 to 4/1/25
1 Year Ago
7/1/23 to 6/30/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
13 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$395.71$385.47$385.67$326.53
Forecasted Upside3.26% Upside1.10% Upside11.51% Upside1.63% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HCA Healthcare Stock vs. The Competition

TypeHCA HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.74
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside3.98% Upside8,715.54% Upside12.49% Upside
News Sentiment Rating
Positive News

See Recent HCA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/23/2025Royal Bank Of Canada
4 of 5 stars
Ben Hendrix
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$376.00 ➝ $404.00+6.79%
6/9/2025Morgan Stanley
3 of 5 stars
Craig Hettenbach
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetEqual Weight ➝ Equal Weight$355.00 ➝ $410.00+10.43%
6/2/2025Stephens
4 of 5 stars
R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetOverweight ➝ Overweight$366.00 ➝ $416.00+9.44%
5/29/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$320.00 ➝ $385.00+1.76%
4/15/2025Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/15/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Neutral$396.00 ➝ $336.00-1.39%
4/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
1/27/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Fischbeck
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$380.00 ➝ $370.00+12.36%
1/27/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$405.00 ➝ $405.00+29.60%
1/7/2025KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Gillmor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$420.00 ➝ $370.00+20.54%
1/6/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$430.00 ➝ $390.00+31.45%
12/17/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$380.00+22.74%
11/22/2024Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Ransom
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/28/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$450.00 ➝ $440.00+22.05%
10/28/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$390.00 ➝ $400.00+10.22%
8/29/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Lake
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/14/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$405.00 ➝ $438.00+18.74%
7/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$367.00 ➝ $396.00+16.32%
6/28/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$359.00 ➝ $375.00+14.85%
1/4/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$277.00 ➝ $301.00+9.85%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$271.00+5.23%
10/25/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$325.00 ➝ $275.00+21.19%
10/25/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$324.00 ➝ $279.00+22.87%
7/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$311.00 ➝ $316.00+14.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:50 PM ET.


Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 29, 2025. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

  • The company reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
  • HCA Healthcare, Inc. has demonstrated impressive revenue growth, with a year-over-year increase, suggesting a solid demand for its healthcare services.
  • The current stock price is around $369, reflecting a strong market position and investor confidence in the company's future prospects.
  • HCA Healthcare, Inc. has a high return on equity, showcasing its efficiency in generating profits from shareholders' equity, which is attractive to investors.
  • The company has a low dividend payout ratio, allowing for reinvestment in growth opportunities while still providing a modest dividend yield to shareholders.

HCA Healthcare
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

  • Recent insider selling by the COO may raise concerns about the company's future performance and management's confidence in its stock.
  • Some analysts have downgraded their ratings on HCA Healthcare, indicating potential caution in the market regarding its stock performance.
  • The healthcare sector can be highly volatile, influenced by regulatory changes and market conditions, which may pose risks to investors.
  • Despite strong earnings, the company's stock price may face pressure from broader market trends or economic uncertainties.
  • HCA Healthcare, Inc. has a relatively low dividend yield, which may not be appealing to income-focused investors seeking higher returns from dividends.

HCA Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $395.71, with a high forecast of $440.00 and a low forecast of $336.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last year. There are currently 7 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCA shares.

According to analysts, HCA Healthcare's stock has a predicted upside of 3.26% based on their 12-month stock forecasts.

Over the previous 90 days, HCA Healthcare's stock had 2 upgrades and 1 downgrade by analysts.

HCA Healthcare has been rated by research analysts at Baird R W, Barclays, Guggenheim, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, Stephens, and Wells Fargo & Company in the past 90 days.

Analysts like HCA Healthcare less than other "medical" companies. The consensus rating score for HCA Healthcare is 2.74 while the average consensus rating score for "medical" companies is 2.81. Learn more on how HCA compares to other companies.


This page (NYSE:HCA) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners